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COVID-19 in Hematology patients: Real World 
Experience in Hospitals in the UK West Midlands
Abstract
Objectives: This study aimed to understand the consequences of coronavirus disease 2019 (COVID-19) in patients diagnosed with haematological conditions, 
malignant and non-malignant.
Method: A detailed insight into the first 112 patients with comorbidity of haematological conditions and COVID-19, admitted into nine National Health Services 
Trusts in the West Midlands Area of the United Kingdom, between 1st of March 2020 and 31st May 2020. 
Results: In the study cohort, 82% of patients had a malignant haematological disorder whilst 18% had a non-malignant haematological condition. Increasing 
age, breathlessness, reduction in oxygen saturation under 90% and abnormal chest x-ray were independently associated with higher mortality. Other long term 
co-morbidities did not present adverse impacts in this population. Survival analysis demonstrated that the COVID-19 severity score had a significant adverse 
correlation on patient outcome. COVID-19 patients who were classified as low risk, based on their primary haematological condition, showed significantly shorter 
survival time than those in the high risk category, which might be due to the shielding strategy for high infection risk patients. 
Conclusion: The 55% overall mortality in this cohort suggests that patients with haematological conditions had a higher mortality rate than patients with other 
acute, chronic or long term conditions.
Significance: Previous studies have suggested poor outcomes for COVID‐19 infection in patients with haematological cancers, with short‐term mortality rates 
ranging from 32% to 62%. We report here the outcome of COVID-19 infection in patients with haematological conditions with both malignant and non-malignant, 
admitted to secondary care in acute care hospitals of the UK West Midlands. This study also examined the impact of chemo immunotherapy on outcomes from 
COVID-19 infection. This will be useful information to guide decision making during this second UK national lockdown.
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Introduction
Human infections with the new type of Coronavirus classified as 
‘severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were 
first reported in December 2019 [1]. The World Health Organisation (WHO) 
named the syndrome produced by the virus ‘Covid-19.’ As infections rapidly 
proliferated, it became apparent that there were several specific patterns of 
disease progression [2]. Respiratory involvement is common, but ranges 
from a dry cough to breathlessness, low oxygen saturations and lung field 
changes on X-ray [3]. The majority of those infected experience only mild 
to moderate symptoms; cough, sneezing, malaise and the initially unknown 
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but now well recognised loss of taste and smell, but around 5-10% of cases 
experience severe or critical illness including pneumonia and respiratory 
failure [4,5]. Although some cases of rapid progression have been reported, 
the pattern most commonly observed has been mild to moderate disease 
at presentation followed by a severe worsening of respiratory function 
9-12 days post onset [2,5,6]. It has been further noted that worsening 
of respiratory function is associated with raised D-dimer levels, raised 
prothrombin time, low white cell count and X-ray opacities [5].
Faced with this new epidemic, with no established treatment strategies, 
hospitals around the world, despite massive workloads, began collecting 
prospective data to be later analysed to inform the future management 
of this condition. This data was collected at a time of great stress, and 
on a constantly moving stage, but has allowed important lessons to be 
learned. Publication of the findings from a number of hospitals in a range of 
countries provides the potential to combine these studies for meta-analysis, 
potentially providing stronger evidence to improve our management of this 
condition [7-9]. 
Prospective data collection and review has already produced clear 
benefits; the importance of lung function at presentation quickly emerged 
as an important prognostic factor [10]. Evaluation of COVID-19 therapy 
within the ‘RECOVERY’ trial, showing benefits of dexamethasone therapy 
in patients requiring respiratory support [11] has raised many questions, as 
steroids are an integral part of many chemotherapy regimens.
This study explored the trends that emerged from 112 patients with 
haematological conditions (malignant and non-malignant) reviewed at 
haematology services at the nine hospitals in the West Midlands region 
of the United Kingdom, from the start of the outbreak, in whom COVID-19 
infection had been confirmed. The objectives of this study were three fold: 
First, examine the mortality of patients with haematological conditions 
with SARS-CoV-2 viral infection, second, investigate the possible factors 
that may significantly impact the outcome in haematology patients with 
COVID-19 and lastly, examine the likelihood of any adverse role of recent 
chemo-immunotherapy continuation or cessation.
Method and Data Description
This was a multicentre retrospective study, carried out in nine hospitals 
in the West Midlands under the West Midlands Research Consortium 
(WMRC). All adult patients with underlying haematological disorder 
(both malignant and non-malignant) and confirmed COVID-19 diagnosed 
between 1st March 2020 and 31st May 2020 were included in the study. 
A standardised data collection form was used across all nine hospitals 
for collecting demographic, clinical, laboratory, radiological and outcome 
data. SARS-CoV-2 was diagnosed by real time polymerase chain reaction 
(RT-PCR). The study received ethical clearance waiver for the audit of 
the medical records from the research and development committees of all 
participating hospitals.
Patients were categorized based on their underlying haematological 
conditions to have high, intermediate, or low risk disease status. All patients 
on active chemotherapy, having relapsed and or refractory disease, acute 
myeloid leukaemia with adverse cytogenetics, post auto or allogeneic 
transplant, extranodal T-cell lymphoma, multiple myeloma, post splenectomy 
and sickle cell disease were categorized as high risk. Intermediate risk 
included Hodgkin’s and non-Hodgkin’s lymphoma patients not on any 
treatment, myeloproliferative neoplasms and myelodysplastic syndrome. 
The low risk cohort were patients with non-malignant haematological 
conditions and patients in complete remission who had completed treatment 
more than six months ago which was adapted from the 2012 published 
categorisation for people diagnosed with haematological conditions [12]. 
Patients were identified as having severe COVID-19 infection on the 
presence of any one of the following: oxygen saturation ≤90% on room 
air, respiratory rate higher than or equal to ≥ breaths per minute; bilateral 
infiltrates on lung imaging as defined in WHO guidelines [13].
Statistical analysis was carried out using IBM SPSS® software version 
26 and STATA SE®16. Kruskal–Wallis tests were used for comparing 
observations for the hazard event, i.e. survival and non-survival. For testing 
of three groups, the ANOVA one way test, coupled with the Tukey post-test 
was utilized. Using logistic regression and the Cox-proportional hazards 
model, the impact, and the survival estimates of these various factors was 
studied.
Results
Preliminary findings were presented in a letter earlier to attract specialist’s 
attention to our findings for this unique population of patients diagnosed 
with haematological disorders [14]. Comparing outcomes (alive or dead) 
for patients from black, Asian and minority ethnic groups (BAME) and white 
ethnic background, there was no significant difference identified in this 
study, with 56% from each category (BAME or White) died. However, 84% 
of this study cohort was white Caucasian.
Table 1 summarizes the general characteristics of the patients: the median 
age of the study cohort was 70 years (IQR 61,78; range 18,95). Men (57.5%) 
were the majority compared to women (41.5%). Regarding ethnicity, 76% of 
patients were Caucasian. There were 82% of patients who had a malignant 
haematological disorder whereas 18% had non-malignant haematological 
conditions. The most common haematological condition in our cohort was 
multiple myeloma (16.8%) followed by 13.2% of acute myeloid leukaemia 
(AML) and 13.2% of diffuse large B-cell lymphoma (DLBCL). Most of the 
patients (60%) fell into the high infection risk category due to their primary 
haematological disease. The commonest co-morbidities in this study cohort 
were hypertension (41%), ischaemic heart disease (22%), diabetes mellitus 
(21%), chronic lung disease (20%) and obesity (10%).
Population Observation
Proportion out 
of patients with 
available data 
Total Number with 
available data
Number of patients 
Survived with 
available data 
Number of patients 
Died with available 
data 
Sex
Male                                                            
Female                                                        
Not recorded                                               
White                                                   
Black                                            
Asian                                                            
Not recorded                                              
Malignant                                                    
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Patients, who died, had a greater proportion of symptoms. Of all patients, 
30% had no documented co-morbidity. The symptoms experienced on 
admission are detailed in. The most common were shortness of breath 
(58%), cough (43%) and fever (33%). Only 4.4% of patients were completely 
asymptomatic and 63% of patients had severe COVID-19 symptoms at 
presentation. There were 4% of patients were either seen as outpatients 
or died before admission, the remaining 96% of patients were admitted to 
hospital. The median time from symptom onset to hospital admission was 
two days (range 0-35 days), 17% of patients required admission to a high 
dependency or intensive care unit, with 11% requiring invasive ventilation. 
The median number of days of intensive therapy unit (ITU) stay was seven 
days. The median age of patients admitted to ITU was 61.5 years. Based on 
the UK government COVID-19 statistical data (coronavirus.data.gov.uk) on 
the 19/6/2020, there were 300,469 confirmed COVID-19 cases and 42,285 
deaths, indicating mortality rate of 14% of all infections and 30% for hospital 
patients. In this study population of haematological patients’, the mortality 
was 55% (RR 1.8). From patients deemed as high risk for poor prognosis 
(n=68), 59% died. Under the system in use in local National Health Service 
(NHS) Trusts at the time, 91 patients were categorised as severe and 59% 
of those died. The study sample had a small number of patients with non-
malignant conditions (n=20). Of those with malignancy, 53% died compared 
to 60% of those with non-malignant conditions. This preliminary finding may 
suggest that pre-existing haematological conditions influence prognosis 
and survival outcomes (Table 2).
Symptoms Proportion out of 
patients with available 
data







Positive finding of 
respiratory imaging
20% 108
Heart rate equal and 
above 120 bpm
5% 92
Respiratory rate equal 
and above 24 rpm
23% 92
Oxygen saturation 
(SpO2) equal and 
under 90%
16% 92
Table 2. COVID-19 Symptoms on Presentation
The study cohort chest x-ray findings (p=0.002), pulmonary infiltrates on 
computerised tomography (CT) scan (p=0.023), age (p=0.032) and obesity 
(odd’s ratio: 2.34) were independent variables and significant predictors 
of mortality. Risk factors identified in other series such as diabetes or 
hypertension or ethnicity, were not associated with an adverse outcome 
in this cohort of patients diagnosed with haematological conditions 
pre-COVID19. Table 3 reports on the significance value of the various 
observations categorized in two groups, (survival and death). It shows low 
oxygen saturation, increased respiratory rate and high C-reactive protein 
(CRP) were statistically significant predictors of outcome. The prothrombin 
time (PT) was slightly lower, the activated partial thromboplastin time 
(APTT) was slightly higher, and the Fibrin Degradation Fragment (D-dimer) 
was slightly higher in those died suggesting greater susceptibility to 
thromboembolism. Additionally, the results showed increased risk of clotting 
in both dead and surviving patients. While inflammation can increase ferritin 
levels, in our sample ferritin elevation was an expected finding, considering 
the population type and the haematological conditions present. In this study 
lymphocytes showed slight elevation in those died but neutrophils remained 
within range. Lastly the elevation in lactate dehydrogenase (LDH) may 
indicate tissue damage.









Heart Rate 1.35 0.181 Breathlessness 6.416** .011













Diabetes                                                       
Ischaemic Heart 
Disease (IHD)
Hypertension                         
Chronic lung disease          
Obesity                                                            





























Not admitted (died or 
short stay) 4%
Respiratory Support
Intubated-ventilated             
Respiratory support 









Time from onset of 
symptoms to outcome 
in days
Time to recovery 
(median–SD) and ra
nge                                                      
Time to death 
(median–SD) and ra






Table 1. Baseline Population Characteristics Table 1. Baseline Population Characteristics
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D Dimers 1.08 0.296
Note: *** indicates significant at 1 percent level, ** indicates significant 
at 5 percent level and * indicates significance at 10 percent level. The 
p-values are provided in parenthesis. a Positive i.e. abnormal finding on 
x-ray
Table 3. Univariate Analysis of continuous and categorical observations
To gain deeper insights on the survival rates and the marginal effects 
of each of the parameters, we examined the impact of age, COVID-19 
severity (based on the WHO classification) and malignant or non-malignant 
haematological condition on mortality. Using logistic regression and the 
Cox-proportional hazards model, the impact, and the survival estimates 
of these various factors were examined. We demonstrate that the mean 
survival time for the disease based risk category are 11 days, 13 days and 
7 days for categories, High, Intermediate and Low, respectively. The mean 
survival time for the COVID-19 severity category is 11 days for both severe 
and non-severe classification. The mean survival times for the malignancy 
classification are 11 days and 10 days for malignant and non-malignant 















0 20 40 60
Analysis Time
High Risk/Covid non-Severe High Risk/Covid Severe
Intermediate Risk/Covid non-Severe Intermediate Risk/Covid Severe
Low Risk/Covid non-Severe Low Risk/Covid Severe
Figure 1. Kaplan-Meier survival estimates of COVID-19 mortality
Figure 1 shows the graph of the survival functions. The mean survival time 
for the disease-based risk category are 11 days, 13 days and 7 days for 
categories, High, Intermediate and Low, respectively. The mean survival 
time for the COVID-19 severity category is 11 days for both severe and 
non-severe classification. The mean survival times for the malignancy 
classification are 11 days and 10 days for malignant and non-malignant 
categories, respectively. The X-axis represents the Analysis Time, which 
is the duration in days between the dates of onset of COVID-19 symptoms 
and death.
Using logistic regression and a predictive marginal model, key factors 
affecting mortality were examined. Table 4 reports on the odds ratios and 
the marginal effects of our estimates model. An odds ratio of greater than 
one indicates that the variable has a positive impact on death. COVID-19 
severity has the highest impact on mortality in our cohort. The marginal 
effect shows that, while severity of COVID-19 and age increases the 
chances of their death, by 24% and 15%, respectively, non-malignancy 
reduces the mortality. The Wald Chi-square statistic suggests a significant 
relationship between the independent variables and mortality.
Factors Odds Ratio (OR)

























Note: The table presents the robust logistic regression model results 
along with the marginal effects. An odds ratio of greater than one sug-
gests that the variable has a positive impact on the event and a value of 
less than one state otherwise. The Wald Chi-square statistic suggests 
that lays significant relationship between the independent variables and 
the event. *** indicates significant at 1 percent level, ** indicates signifi-
cant at 5 percent level and * indicates significance at 10 percent level. 
The p-values are provided in parenthesis.
Table 4. Odds ratios and the marginal effects of the key factors
When a multivariate analysis was performed to examine the odds ratio of 
the various significant factors, we found that increase in respiratory rate 
(p=0.010) and COVID-19 severity (p=0.008) were significant at 1% level. 
Breathlessness (p=0.002), heart rate (p=0.002), oxygen saturation (SpO2, 
p=0.035), pulmonary infiltrates (CT) (p=0.026), APTT (p=0.016) high risk 
group (p=0.019) indicated significant at 5% level. Obesity (p=0.058), chest 
imaging positive (p=0.012), age and high risk group (p=0.080), Fibrinogen 
(p=0.086) indicates significance at 10% level (13). Of interest is that obesity 
negatively impacted on survival? In our model, we also included several 
interaction variables that significantly affected COVID-19 mortality. Amongst 
the variables concerned, COVID-19 severity along with disease bask risk 
profile had the most significant impact (Figure 2).
Figure 2. Kaplan-Meier survival estimates of obesity
The X-axis represents the Analysis Time, which is the duration in days 
between the dates of onset of COVID-19 symptoms and death’.
Discussion
This is the largest series of patients with both malignant and non-malignant 
haematological conditions infected by SARS-CoV-2. This study highlights 
patients with haematological conditions may present with COVID-19 
differently to the general population. Fever was observed in 33% of our 
patient cohort as compared to 71% in the Clinical Characterisation 
Protocol UK (CCP-UK) study [15]. Similar to previous reports in the general 
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population and specific blood cancers, older age was associated with higher 
mortality in our cohort as well. However other co-morbidities like diabetes or 
hypertension did not confer adverse outcome [16]. Interestingly there was 
no suggestion of poor outcomes in BAME patients; this probably reflects the 
small sample size of this patient group in our cohort.
Overall mortality in our cohort was 55%. This higher mortality could be 
due to this cohort being retrospectively reported during the early peak of 
COVID-19 pandemic in our region. Also, West Midlands was the second 
most affected region in the country. Another factor is that polymerase chain 
reaction (PCR) testing to detect COVID-19 infection early in the peak was 
reserved for unwell patients attending hospital, and this study is likely to 
significantly under report outpatient and less symptomatic cases. Only a 
small proportion of this study cohort had their oxygen support data was 
collected and only small proportion of those received ITU support, as 10.7% 
compared 18% UK wide [15]. Similar higher mortality among patients with 
haematological malignancies was recently reported by the Italian group 
[17]. Initial results of the RECOVERY trial [11] have shown survival benefit 
from the use of dexamethasone in the general population and the WMRC 
is eagerly waiting to see if this result is also applicable for patients with 
haematological conditions.
Atypical presentation, noticeably lower proportion with fever (33%) with of 
COVID-19 as highlighted in our series may have led to delay in patients 
seeking medical attention. Also, strict instructions to shield may have led 
to delayed presentation. Mortality observed in disease specific cohorts like 
chronic lymphocytic leukaemia (CLL) is around 35% which is lower than our 
cohort (55%). This may be due to the possible protective effect of Bruton's 
tyrosine kinase (BTK) inhibitor therapy in CLL patients [16,18]. This study 
results underlines the importance of paying close attention to inflammatory 
markers and identifying signs of developing coagulopathy [19].
Conclusion
As the pandemic has developed many lessons have been learned and 
guidelines have evolved. The outcomes identified are still cause for 
concern and reflection. In this series the presence of lung infiltrates and 
other underlying lung pathology denotes a particularly high risk group. 
Contrary to expectations, the study cohort highlights that being on systemic 
chemotherapy did not confer excess risk of mortality. This suggests primary 
therapy for the haematological condition could be possibly continued to 
avoid adverse impact on their underlying haematological condition.
Study limitation
This study was carried out rapidly at the height of the pandemic, where 
the uncertainty and the workload were immense. As a result, not all data 
parameters were available for every patient. This report also reflects the 
outcome of hospital managed patients. This may not mirror the outcome 
for haematological patients in the community. Despite these limitations, 
to the best of our knowledge this is one of the largest reports describing 
the outcome in COVID-19 in malignant and non-malignant haematology 
patients from UK.
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